Patents by Inventor Armin Pause

Armin Pause has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purified active HCV NS2/3 protease
    Publication number: 20070172936
    Abstract: A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it with a reducing agent and lauryldiethylamine oxide (LDAO) in the presence of reduced concentration of chaotropic agent or polar additive. The invention further comprises a method for activating this refolded inactive NS2/3 protease by adding an activation detergent. This method produces large amounts of the active NS2/3 protease to allow small molecules and ligands to be screened as potential inhibitors of NS2/3 protease, which may be useful as therapeutic agents against HCV.
    Type: Application
    Filed: September 9, 2005
    Publication date: July 26, 2007
    Applicant: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Diane Thibeault, Daniel Lamarre, Roger Maurice, Louise Pilote, Armin Pause
  • Purified active HCV NS2/3 protease
    Patent number: 6815159
    Abstract: A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it with a reducing agent and lauryldiethylamine oxide (LDAO) in the presence of reduced concentration of chaotropic agent or polar additive. The invention further comprises a method for activating this refolded inactive NS2/3 protease by adding an activation detergent. This method produces large amounts of the active NS2/3 protease to allow small molecules and ligands to be screened as potential inhibitors of NS2/3 protease, which may be useful as therapeutic agents against HCV.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: November 9, 2004
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Diane Thibeault, Daniel Lamarre, Roger Maurice, Louise Pilote, Armin Pause
  • Purified active HCV NS2/3 protease
    Publication number: 20020192640
    Abstract: A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it with a reducing agent and lauryldiethylamine oxide (LDAO) in the presence of reduced concentration of chaotropic agent or polar additive. The invention further comprises a method for activating this refolded inactive NS2/3 protease by adding an activation detergent. This method produces large amounts of the active NS2/3 protease to allow small molecules and ligands to be screened as potential inhibitors of NS2/3 protease, which may be useful as therapeutic agents against HCV.
    Type: Application
    Filed: December 14, 2001
    Publication date: December 19, 2002
    Inventors: Diane Thibeault, Daniel Lamarre, Roger Maurice, Louise Pilote, Armin Pause